2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
5
Mucositis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Febrile Neutropenia
2
Cytokine Release Syndrome
2
Burkitt Lymphoma
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Smoldering Multiple Myeloma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammation
1
Hematologic Neoplasms
1
Early Stage Triple Negative ER Low Breast Cancer
1
Disease Progression
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Adalimumab
19
Etanercept
16
Methotrexate
11
Infliximab
8
tocilizumab
7
Rituximab
7
golimumab
6
Abatacept
6
tofacitinib
5
Tumor Necrosis Factor Inhibitors
5
olokizumab
4
Certolizumab Pegol
4
Antirheumatic Agents
3
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Arthritis, Rheumatoid
×
Interleukin 1 Receptor Antagonist Protein
×
Clear all
NCT00537667
2009-11-26
The SPECTRA Study
Swedish Orphan Biovitrum
Phase 2
Terminated
22 enrolled